|Bid||0.860 x 1300|
|Ask||0.990 x 1400|
|Day's Range||0.8418 - 1.0600|
|52 Week Range||0.8418 - 3.8100|
|Beta (3Y Monthly)||2.26|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of American Depository Shares and warrants of Kitov Pharmaceuticals Holdings, Ltd. (KTOV). OR (2) KITOV AMERICAN DEPOSITORY SHARES OR WARRANTS TO PURCHASE KITOV AMERICAN DEPOSITORY SHARES ON OR ABOUT NOVEMBER 20, 2015 OR ON OR ABOUT JUNE 28, 2016.
TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced the appointment of Gil Efron as the Company’s new Deputy Chief Executive Officer and Chief Financial Officer. Simcha Rock, who has served as Kitov’s Chief Financial Officer since 2013, will retire from that position following a transition with Mr. Efron, and will continue to serve on the Company’s Board of Directors and as a strategic advisor. “On behalf of the entire Board and management team at Kitov, I am immensely grateful to Simcha Rock for his dedication and valuable contributions to Kitov since its inception, including playing a key role in the growth of our business and leading our initial public offering on the NASDAQ.
TEL AVIV, Israel, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that Hadas Reuveni, Ph.D., Chief Technology Officer at Kitov’s subsidiary, TyrNovo Ltd., will present pre-clinical data on NT219, an anti-tumor resistance drug candidate, in a poster session at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held September 30 - October 3, 2018, in New York.
Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that, following a filing by Kitov’s Chairman of the Board and Chief Medical Officer, Dr. Paul Waymack, of a motion to quash a subpoena for documents and testimony served on Dr. Waymack by the Securities and Exchange Commission (“SEC”), the SEC has commenced an action to enforce the subpoena. As stated by the SEC, “The application does not reflect a determination by the SEC or its staff that Waymack or Kitov Pharmaceuticals has violated any provisions of the federal securities laws or any provisions at issue in the Israel Securities Authority's investigation”.
Stock Research Monitor: KTOV, LOXO, and MDGL LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration . Today, WallStEquities.com ...
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / It was FDA news that sent shares of Kitov Pharma blasting off on Thursday. Shares of Clearside Biomedical sunk despite positive topline results being announced ...
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Kitov Pharma Ltd (NASDAQ: KTOV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KTOV as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a definitive license and commercialization deal with China-based Hebei Changshan Biochemical Pharmaceutical Co., Ltd ("Changshan"), granting the latter exclusive rights to import, manufacture, and distribute the Company's lead drug candidate, Consensi™, in China.
TEL AVIV, Israel, April 13, 2018 /PRNewswire/ -- Kitov Pharma (NASDAQ and TASE: KTOV), today announced that TyrNovo Ltd., a company majority-owned by Kitov, will present pre-clinical data on TyrNovo's anti-tumor resistance drug candidate, NT219, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2018, to be held on April 14-18, at the McCormick Place, Chicago, Illinois.
TEL AVIV, Israel, March 8, 2018 /PRNewswire/ -- Kitov Pharmaceuticals (KTOV) (KTOV), an innovative biopharmaceutical company, announced today that Dr. Gil Ben-Menachem, VP Business Development of TyrNovo, a Kitov Pharmaceuticals company, will present recent results from pre-clinical studies with NT219, a novel dual inhibitor of STAT3 and IRS1/2, at the 2018 BIO-Europe Spring® Conference at the RAI Convention Center, in Amsterdam, The Netherlands. NT219 is an innovative, unique small molecule targeting IRS1/2 and STAT, two signal proteins that are part of an anti-cancer drug resistance mechanism.
TASE: KTOV), an innovative biopharmaceutical company, announced today that it filed its Annual Report for 2017 on Form 20-F, including its full financial results for the year ended December 31, 2017. Consensi™, a combination drug that simultaneously treats pain caused by osteoarthritis and treats hypertension, is comprised of two FDA approved drugs, celecoxib (Celebrex®), an NSAID, for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a drug designed to treat hypertension.